Abbott has won U.S. approval for the peripheral-artery-disease stent it bought last year

Abbott announced on Friday that its Supera Peripheral Stent System has got the FDA's approval to treat blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). Last July, Abbott announced a $310 million deal to acquire Supera's developer, Texas-based Idev Technologies, which already had Supera before the FDA for review. The self-expanding nitinol stent already has a CE mark. In its U.S. trial, Idev brought data from 1,500 patients around the world. The disease, according to Abbott, affects 12% to 20% of Americans age 65 or over, causing leg pain and increased risk of blood clot or stroke. Supera is designed to mimic the body's natural function while propping open blood vessels. Release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.